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In Brief A systematic investigation of how the three ApoE isoforms may contribute to Alzheimer's disease pathogenesis reveals a direct role for ApoE in driving levels of APP and amyloid-b levels.
INTRODUCTION Apolipoprotein E (ApoE), a major component of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) circulating in blood, mediates uptake of these lipoproteins into cells by binding to ApoE receptors, principally the LDL receptor (Goldstein and Brown, 2015) . ApoE is highly expressed in brain, primarily in astrocytes, but its function in brain remains unclear (Holtzman et al., 2012; Wang and Eckel, 2014) . In addition to LDL receptors, several related ApoE receptors are expressed throughout the body. Many of these other ApoE receptors bind additional ligands and perform central functions during development. For example, the LDL-receptor-related proteins VLDLR and ApoER2 bind reelin and regulate cortical development (Trommsdorff et al., 1999) , LDL-receptor-related proteins 5 and 6 (Lrp5 and Lrp6) are co-receptors for wnts (Tamai et al., 2000) , and LDL-receptor-related protein Lrp2 is an auxiliary receptor for sonic hedgehog (Christ et al., 2012) . Moreover, ApoE exhibits signaling properties in dissociated cultures of rodent neurons and activates mitogen-activated protein (MAP) kinases (Ohkubo et al., 2001; Qiu et al., 2004) . Several MAP kinases are prominently expressed in brain, including the MAP kinase kinase kinase DLK (for ''dual leucine-zipper kinase''), which has been implicated both in the degeneration and regeneration of neurons (Tedeschi and Bradke, 2013; Lu et al., 2014) . In C. elegans and Drosophila, regeneration of injured neurons requires DLK activation (Hammarlund et al., 2009; Yan et al., 2009; Shin et al., 2012) . In rodents, conversely, DLK mediates neuronal cell death during development and contributes to excitotoxic neurodegeneration (Chen et al., 2012) . However, the precise relation of ApoE receptor binding to MAP kinase activation has not been explored.
Human ApoE is expressed in three genetic isoforms, ApoE2, ApoE3, and ApoE4, which encode proteins that differ only in two residues. Strikingly, the ApoE4 allele is the most important genetic risk factor for Alzheimer's disease (AD), whereas the ApoE2 allele is protective (Strittmatter et al., 1993) . How ApoE isoforms predispose to AD, or protect against it, is incompletely understood (Holtzman et al., 2012; Kanekiyo et al., 2014) . A central feature of AD pathology is formation of amyloid-b (Ab) oligomers and plaques (Pimplikar et al., 2010; De Strooper and Karran, 2016; Goedert, 2015) . Although the precise role of Ab in AD remains debated, Ab clearly constitutes a central component of AD pathogenesis that correlates with neuronal cell death and that may perform a causative role in AD pathogenesis (Goedert, 2015; De Strooper and Karran, 2016) . Both in AD patients and in cognitively apparently normal people, ApoE4 is associated with increased Ab accumulation in brain (Schmechel et al., 1993; Fouquet et al., 2014) . ApoE binds Ab in its delipidated form, but this binding is probably not responsible for the effect of ApoE4 on Ab accumulation because ApoE does not bind Ab as a native lipoprotein (Verghese et al., 2013) . ApoE4 enhances Ab oligomerization, suggesting that ApoE4 could predispose to AD by increasing toxic Ab oligomers (Hashimoto et al., 2012) . Mice express only a single ApoE allele; exchanging endogenous ApoE in mice with human ApoE2, ApoE3, and ApoE4 produces complex effects that include changes in Ab aggregation and clearance (Castellano et al., 2011; Fryer et al., 2005) . (A) Experimental design. Human neurons (iN cells) were generated from H1 ESCs by forced expression of neurogenin-2 (Ngn2) and cultured either on mouse glia (green), which secrete copious amounts of ApoE; on murine embryonic fibroblasts (MEFs), which secrete no ApoE (blue); or on Matrigel (black lines). (B) Representative images of human neurons at day 10 after induction (D10) cultured on glia, MEFs, or Matrigel and sparsely labeled by EGFP transfection. (C) Survival, soma size, and neurite length of human neurons cultured on glia, MEFs, or Matrigel. (D) Screening 24 secreted proteins that are abundantly produced by cultured mouse glia reveals three factors (ApoE, IGF2, and IGFBP2) that induce Ab40 and Ab42 secretion from human neurons cultured on MEFs. Various factors were produced as human proteins in HEK293 cells (names reflect gene symbols) and added to human neurons on MEFs at D10. Media from treated neurons were analyzed by ELISA at D12. (E) ApoE2, ApoE3, and ApoE4 (all at 10 mg/mL; from D10 to 12) differentially stimulate Ab40 and Ab42 secretion by human neurons cultured on MEFs with an ApoE4 > ApoE3 > ApoE2 potency rank order, thereby partially rescuing the decrease in Ab40 and Ab42 secretion when neurons are co-cultured with MEFs
(legend continued on next page)
Collectively, these observations suggest that ApoE may normally function in brain as a lipid transport and/or signaling molecule and that ApoE4 may predispose to AD because it affects the production, clearance, and/or toxicity of Ab (Holtzman et al., 2012) . However, these observations are based on experiments that analyzed glial cells and neurons together-either in vitro or in vivo-and focused on rodents. Here, we took a different approach and examined the effects of recombinant ApoE2, ApoE3, and ApoE4 on human neurons that were cultured without glia to exclude the confounding influence of secreted factors produced by glia, including glial ApoE. We show that ApoE is indeed a signaling molecule, demonstrate that ApoE activates an unusual MAP kinase signaling cascade, document that this cascade stimulates cFos phosphorylation and APP gene transcription, and show that this stimulation leads to increased amyloid-b precursor protein (APP) and Ab synthesis. Most importantly, we show that the intrinsic efficacy in activating this pathway differs dramatically between ApoE2, ApoE3, and ApoE4, mirroring their relative effect on AD pathogenesis. Thus, our data uncover an ApoE-dependent signaling pathway that may perform a general role in brain as well as contribute a significant component to AD pathogenesis.
RESULTS

ApoE Proteins Stimulate Neuronal Ab Production with an ApoE4 > ApoE3 > ApoE2 Potency Rank Order
We trans-differentiated human embryonic stem cells (ESCs) into human excitatory neurons using transient expression of Ngn2 (Figures 1A, 1B, and S1A; . In previous studies (e.g., Pak et al., 2015; Patzke et al., 2016) , we co-cultured human neurons with mouse glia because glia secretes multiple factors that support survival and synaptogenesis (Ullian et al., 2001) . However, here, we aimed to develop an approach that would allow examining the effects of glial factors on neurons, making it necessary to culture human neurons without glia. Toward this goal, we compared human neurons cultured on glia with neurons cultured on mouse embryonic fibroblasts (MEFs) or on Matrigel alone (Figures 1B and 1C) . We found that, under all conditions, human neurons appeared to develop normally with no major change in dendritic arborization, but neurons plated on Matrigel alone did not survive as well as neurons co-cultured with glia or MEFs ( Figure 1C ). Therefore, we utilized human neurons cultured on MEFs as a standard approach.
As expected, neurons grown in the absence of glia exhibited decreased synaptogenesis. Interestingly, however, neurons co-cultured with glia secreted 2-to 3-fold more Ab40 and Ab42 than neurons co-cultured with MEFs, suggesting that a secreted glial signaling factor stimulates neuronal Ab synthesis. Indeed, adding conditioned medium from glial cultures to human neurons significantly stimulated Ab40 and Ab42 production (Figure 1D) . We thus asked which glial factor(s) might be responsible.
Based on RNA sequencing (RNA-seq) data from glia, we selected 24 abundant secreted glial proteins that we produced in transfected HEK293 cells. Adding these factors to neurons cultured on MEFs revealed that three proteins, ApoE, Igf2, and IgfBP2, significantly increased Ab production ( Figure 1D ). Because ApoE is an abundant secreted glial protein that is critically important for AD pathogenesis (Holtzman et al., 2012) and is nearly undetectable in neurons or MEFs (Figure S1B ), the induction of Ab secretion by ApoE was intriguing, prompting us to focus on studying its mechanism of action.
We first asked whether the three different human genetic ApoE variants that are differentially linked to AD-ApoE2, ApoE3, and ApoE4-differentially stimulate Ab synthesis in human neurons. When we incubated neurons cultured on MEFs with recombinant human ApoE2, ApoE3, or ApoE4 (all at 10 mg/mL for 48 hr), we found that all three ApoE isoforms robustly enhanced Ab synthesis but with strikingly different efficacy (ApoE4 > ApoE3 > ApoE2). This differential efficacy was observed for total Ab, Ab40, or Ab42 and for secreted as well as cellular Ab (Figures 1E, S1C, and S1D) and was unrelated to a-or b-secretase expression ( Figure S1E ). Moreover, the differential efficacy of ApoE2, ApoE3, or ApoE4 was independently reproduced with human neurons generated from two different induced pluripotent stem cell (iPSC) lines (Figures S1F and S1G). When we added ApoE to neurons co-cultured with glia, however, we observed no additional increase in Ab production, presumably because ApoE and other glial factors already maximally stimulate Ab synthesis ( Figures 1D and S1H) . Control experiments confirmed that our Ab measurements monitored exclusively human neuronal Ab synthesis and were not contaminated by Ab from other sources (Figures S1I and S1J). Thus, ApoE secreted by cultured glia massively stimulates Ab synthesis in human neurons, and ApoE2, ApoE3, and ApoE4 exhibit differential potency in stimulating Ab synthesis with a relative effect size that parallels the effect size of these protein variants as risk factors on AD pathogenesis (Strittmatter et al., 1993 (Ohkubo et al., 2001; Qiu et al., 2004) . Confirming these studies, we found that ApoE increased ERK1/2 phosphorylation in human neurons 2-to 5-fold (Figure 2A) . Strikingly, ApoE2, ApoE3, and ApoE4 again exhibited the same differential efficacy in this stimulation as for Ab synthesis (ApoE4 > ApoE3 > ApoE2).
Using ApoE3 as a standard ApoE isoform, we probed the mechanism of ApoE-induced ERK1/2 activation. RAP, a protein that prevents binding of ApoE to surface receptors (Herz et al., 1991) , blocked ApoE-triggered phosphorylation of ERK1/2 (Figures 2B , S2A, and S2B), suggesting that ApoE acts by binding to instead of glia. Summary graphs show total concentrations of Ab (left), Ab40 (left center), and Ab42 (right middle) in the medium and of the Ab42/Ab40 ratio (right) measured by ELISA at D12. For cellular Ab, Ab40, and Ab42 levels and for similar results for neurons generated from iPSCs, see Figure S1 . Data are means ± SEM (n R 3 independent experiments); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) was evaluated with one-way ANOVA and Tukey's post hoc multiple comparisons. For additional data and controls, see Figure S1 .
ApoE receptors. The MAP kinase kinase inhibitors U0126 and PD98059 (which primarily, but not exclusively, target MEK1/2) also blocked ApoE-stimulated ERK1/2 phosphorylation. In contrast, inhibitors of the phosphatidylinositol 3-kinase (PI3K) Akt (Wortmannin), cJun N-terminal kinase (JNK; SP600125), and src kinase (PP2) had no effect ( Figures 2B, S2A , and S2B). Therefore, ApoE activates a MAP-kinase-signaling pathway in human neurons by binding to ApoE receptors and does so with a potency rank order of ApoE4 > ApoE3 > ApoE2 similar to Ab production.
ApoE Activates a Non-canonical DLK / MKK7 / ERK1/2 MAP Kinase Cascade Human neurons express high levels of the MAP kinase kinase kinase DLK ( Figures S2C and S2D) , which is an attractive candidate for neuronal signaling because it has been implicated in axonal regeneration, synaptogenesis, and neurodegeneration (reviewed in Tedeschi and Bradke, 2013; Lu et al., 2014) . Indeed, we found that ApoE induced a 2-to 4-fold increase in DLK protein levels in human neurons co-cultured with MEFs; this induction again was blocked by RAP, which had no effect on baseline DLK levels ( Figure 2C ). Again, the three human ApoE isoforms increased DLK levels with the same differential potency as for the stimulation of Ab synthesis and ERK1/2 phosphorylation (ApoE4 > ApoE3 > ApoE2; Figure 2C ). Neurons expressed high levels of DLK mRNA, but newly synthesized DLK protein was rapidly degraded (Figure 2E ). Proteasome inhibition with MG132 dramatically increased DLK protein levels under control conditions and occluded subsequent ApoE3-induced increases of DLK levels ( Figure 2D ). ApoE3 had no effect on phosphorylation of JNK1/2/3, the most abundant MAP kinase in neurons, although JNK1/2/3 phosphorylation was stimulated by MG132, which induces a cellular stress response that activates JNKs ( Figure 2D ).
The fact that the proteasome inhibitor MG132 mimics and occludes the effect of ApoE on DLK levels suggests that ApoE increases DLK levels by decreasing rapid proteasomal degradation of DLK. To test this hypothesis, we blocked new protein synthesis in human neurons with cycloheximide in the presence and absence of ApoE3 and measured the decay rate of previously synthesized DLK and ERK1/2 proteins, as well as the degree of ERK1/2 phosphorylation ( Figures 2E and 2F ). We found that DLK was indeed rapidly degraded in the absence of ApoE3, whereas ERK1/2 were relatively stable. ApoE3 significantly decreased the DLK decay rate but had no effect on ERK1/2 protein levels ( Figures 2E and 2F) . As above, ERK1/2 phosphorylation was strongly stimulated by ApoE3 and decayed in parallel with DLK levels after cycloheximide addition (Figures 2F and S2E) . Thus, ApoE activates DLK by decreasing its rapid proteasomal degradation.
Is the ApoE-induced DLK activation responsible for ApoEstimulated ERK1/2 phosphorylation? To address this question, we inhibited DLK using short hairpin RNA (shRNA)-mediated knockdowns or overexpression of MBIP (for MUK/DLK-binding inhibitory protein, an endogenous inhibitor of DLK; Fukuyama et al., 2000) . In addition, we constitutively increased DLK activity by overexpression on the background of the DLK knockdown ( Figures 2G and S2F ). We then measured the effect of these manipulations, which did not impair neuronal survival (Figure S2G ), on ApoE3-induced increases in DLK protein levels and in ERK1/2 phosphorylation and additionally monitored phosphorylation of MKK7, a MAP kinase kinase that is a major DLK target in neurons (Merritt et al., 1999) .
We found that ApoE3 stimulated MKK7 phosphorylation as strongly as ERK1/2 phosphorylation ($4-to 5-fold; Figure 2G ). DLK inhibition by knockdown or MBIP overexpression blocked ApoE3 stimulation of MKK7 and ERK1/2 phosphorylation. Conversely, DLK overexpression induced constitutive ERK1/2 and MKK7 phosphorylation, independent of ApoE3 ( Figure 2G ). None of these manipulations increased JNK1/2/3 phosphorylation, used as a negative control. Knockdown of LZK (a.k.a. MAP3K13), another abundant MAP kinase kinase kinase in ; 25 mM), PI3K kinase (Wortmannin; 0.1 mM), or Src kinase (PP2; 10 mM). Drugs were applied 30 min before a 2-hr ApoE3 (10 mg/mL) incubation at D10. For additional data, see Figure S2 . (C) ApoE2, ApoE3, and ApoE4 cause a rapid, 2-to 3-fold increase in DLK in human neurons cultured on MEFs with an ApoE4 > ApoE3 > ApoE2 potency rank order; recombinant RAP that blocks ApoE receptor binding also blocks ApoE-induced increases in DLK (left, representative immunoblots; right, summary graphs from neurons at D10 treated for 2 hr with 10 mg/mL ApoE). (D) Proteasome inhibitor MG132 (10 mM, applied for 2 hr at D10) increases DLK in human neurons cultured on MEFs similar to ApoE3 (10 mg/mL), thereby occluding the effect of ApoE3 (left); in addition, MG132 stimulates JNK phosphorylation (right). The transcription inhibitor actinomycin D (1 mg/mL) has no effect on the ApoE induction of DLK (left) or JNK phosphorylation (right). (E) ApoE3 significantly slows the rapid turnover of DLK protein (measured by immunoblotting after addition of the protein synthesis inhibitor cycloheximide; 0.1 g/L); left, representative blot; center, summary plots of the fraction of DLK remaining as a function of time after cycloheximide addition; right, summary graphs of the DLK decay rates and calculated half-lives as a function of ApoE3). (F) ApoE3 has no effect on ERK1/2 protein levels that are stable, but ApoE3-stimulated ERK1/2 phosphorylation decays in parallel with DLK protein levels after protein synthesis inhibition (left, summary plots of the fraction of ERK1/2 remaining as a function of time after cycloheximide addition; right, summary plot of the phospho-ERK/total ERK ratio). (G) ApoE3 strongly stimulates MKK7 and ERK1/2 phosphorylation, but not JNK phosphorylation, in human neurons cultured on MEFs (at D10); DLK knockdown with an shRNA or DLK inhibition by MBIP overexpression block ApoE3-induced MKK7 and ERK1/2 phosphorylation, whereas DLK overexpression constitutively activates MKK7 and ERK1/2 phosphorylation (left, representative immunoblots; right, summary graphs). Data are means ± SEM (n R 3 independent experiments); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) was evaluated with one-way ANOVA and Tukey's post hoc test in pairwise comparisons in (A) and (C) and comparisons to control in (B) and (D) and with two-way ANOVA in (E) and (F) .
neurons, also had no effect on ApoE3-induced increases in DLK protein and ERK1/2 phosphorylation ( Figures S2H and S2I) .
Collectively, these data suggest the hypothesis that ApoE activates DLK by increasing its levels; DLK then phosphorylates MKK7, which in turn phosphorylates ERK1/2, but not JNKs ( Figure 3A) . Activated phospho-ERK1/2 may then increase Ab production by enhancing the levels of APP (see below). Although attractive, this hypothesis is inconsistent with current concepts of MAP kinase signaling pathways, which suggest that MKK7 primarily phosphorylates JNKs instead of ERKs (Morrison, 2012) . Thus, we directly tested whether MKK7 mediates ApoE3-induced ERK1/2 phosphorylation. (B) MKK7 inactivation by CRISPR blocks ApoE3 induction of ERK1/2 phosphorylation, whereas MKK7 overexpression constitutively activates ERK1/2 phosphorylation independent of ApoE3. Data are means ± SEM (n R 3 independent experiments); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) was evaluated with one-way ANOVA and Tukey's post hoc test, comparing all conditions to the control without ApoE treatment. For additional data and reagent validation, see Figure S2 . (C) In vitro kinase assay with purified recombinant proteins demonstrates that ApoE3-activated MKK7 directly phosphorylates ERK2. Recombinant human ERK2 was produced in E. coli (left, stain-free SDS-polyacrylamide gel visualized by UV illumination), and naive or ApoE-activated MKK7 was immunopurified from human neurons that overexpressed Flag-tagged MKK7 and were treated at D10 for 2 hr with control or ApoE medium (center; phospho-MKK7 immunoblot). Recombinant ERK2 was then incubated for 30 min at 30 C in the absence (test) and presence of the MEK inhibitor U0126 (50 mM; used as a further control) with Flag beads containing immunoprecipitated control or ApoE-activated MKK7 or with control HA beads. Samples were analyzed by immunoblotting (right).
We inhibited MKK7 in human neurons by CRISPR or activated it by overexpression ( Figures 3B and S2J ). Neither manipulation impaired the ApoE3-induced increase in DLK levels, but both dramatically altered ApoE3-dependent downstream ERK1/2 phosphorylation. MKK7 CRISPR suppressed baseline ERK1/2 phosphorylation and blocked ApoE3-induced ERK1/2 phosphorylation, whereas MKK7 overexpression constitutively enhanced baseline ERK1/2 phosphorylation and rendered it ApoE3 independent ( Figure 3B ). Thus, DLK-mediated MKK7 phosphorylation mediates ERK1/2 phosphorylation in human neurons.
To ensure that MKK7 can actually directly phosphorylate ERK1/2, we produced recombinant ERK2 in bacteria and purified naive and phosphorylated MKK7 by immunoprecipitation from human neurons that overexpressed Flag-tagged MKK7 and that had been treated with control medium or ApoE3 ( Figure 3C ). We then incubated recombinant ERK2 with immunoprecipitated naive or ApoE3-activated MKK7 in the absence or presence of the MEK inhibitor U0126 and measured ERK2 phosphorylation. We observed that MKK7 directly phosphorylated ERK2; ERK2 phosphorylation by MKK7 was enhanced by prior ApoE3-dependent activation of MKK7 and blocked by U0126 ( Figure 3C ). These data confirm that ApoE activates a non-canonical MAP kinase signal transduction pathway consisting of a DLK / MKK7 / ERK1/2 phosphorylation cascade ( Figure 3A ).
ApoE-Mediated MAP Kinase Activation Stimulates APP Gene Transcription
To test how ApoE-induced stimulation of ERK1/2 enhances Ab production, we monitored the effect of ApoE on the levels of APP as the precursor to Ab (Figure 3A) . We found that addition of ApoE2, ApoE3, and ApoE4 to human neurons co-cultured with MEFs increased both APP mRNA and protein levels 3-to 5-fold, again with the same ApoE4 > ApoE3 > ApoE2 potency rank order observed above ( Figures 4A-4C ). This result suggests that ApoE stimulates APP gene transcription. The same ApoEdependent increases in APP mRNA levels were observed in human neurons plated on Matrigel ( Figure 4B ) and were found in independently derived neurons differentiated from iPSC lines (Figures S3A and S3B) . The effects of ApoE on APP levels were concentration and time dependent and were specific to neurons ( Figures S3C-S3E ). Strikingly, ApoE only enhanced APP, but not APLP1 and APLP2 mRNA levels, despite the high homology between APP and APLP1 and APLP2 (Figures 4C, S3A, and S3B). In addition to ApoE, the other glial factors that increased Ab levels in our initial screen also acted by stimulating APP synthesis ( Figures S4A and S4B ).
The ApoE-induced increase in APP mRNA levels was blocked by RAP and by U0126, but not by Wortmannin, suggesting that it is dependent on ApoE binding to surface receptors and on ApoE-induced activation of MAP kinases (Figures 4A and 4C) . Previous studies suggested that ApoE-containing lipoproteins activate neurons by providing cholesterol (Mauch et al., 2001) . Because ApoE protein produced in transfected HEK293 cells is secreted as a lipidated particle that likely contains cholesterol, we tested cholesterol-free ApoE produced in E. coli but observed the same 3-to 5-fold enhancement in APP mRNA levels with the same ApoE4 > ApoE3 > ApoE2 potency rank order as with HEK293-cell-derived ApoE ( Figures 4D and S1C ).
Thus, ApoE acts by a cholesterol-independent, direct receptor action, as also suggested by its sensitivity to RAP. Moreover, we observed that inhibition of DLK by shRNAs or MBIP overexpression and inhibition of MKK7 by CRISPR both blocked the ApoE-induced increase in APP protein . DLK or MKK7 overexpression, conversely, constitutively increased APP mRNA and protein levels ( Figure 4E ). Thus, activation of surface ApoE receptors activates a non-canonical DLK / MKK7 / ERK signaling pathway that increases APP mRNA and APP protein levels.
Similar to Ab synthesis, ApoE3 had no effect on APP levels in human neurons co-cultured with glia (Figures S1H and S5A-S5C), presumably because glial factors fully activate the non-canonical MAP kinase pathway that stimulates APP transcription. Consistent with this hypothesis, DLK knockdowns or DLK inhibition by MBIP dramatically decreased APP and Ab40 and Ab42 levels in neurons co-cultured with glia, whereas DLK overexpression significantly increased these levels ( Figures S5A-S5C ).
These data, viewed together, suggest that ApoE stimulates APP transcription via a non-canonical MAP kinase pathway that involves ERKs, but not JNKs. Consistent with this hypothesis, ApoE3 is taken up into the cell by a receptor-dependent pathway ( Figure S6A ). The exclusion of JNKs in ApoE-dependent signaling is surprising because JNKs are canonical substrates for MKK7 (Morrison, 2012) , JNKs have been identified as downstream targets for DLK in neurodegeneration (Chen et al., 2012) , and APP directly binds to JNK scaffolding proteins (Scheinfeld et al., 2002) . To further examine the role of JNK signaling in ApoE signaling, we tested the role of JIP3, the predominant JNK scaffold in neurons. JIP3 knockdown had no effect on the ApoE3-mediated increase in APP and DKL levels or MKK7 and ERK1/2 phosphorylation but inhibited the MG132-mediated stimulation of MKK7 and JNK phosphorylation as expected (Figures 4F and S4C) . Thus, the JNK pathway is not required for ApoE signaling.
AP-1 Transcription Factor Activation Mediates ApoE Stimulation of APP Transcription
How does ApoE selectively increase APP, but not APLP1 and APLP2 transcription? To examine this question, we used CRISPR interference (CRISPRi) mapping with guide RNAs that were targeted to APP gene promoter sequences (Figure 5A; Larson et al., 2013) . We found that, of six guide RNAs tested, only one guide RNA (sg2) blocked ApoE3-induced increases in APP protein and mRNA levels (Figures 5B, 5C, and S6B). Importantly, CRISPRi with sg2 did not impair ApoE3-induced ERK1/2 phosphorylation and had no effect on baseline APP mRNA and protein levels. Moreover, CRISPRi with sg2 abolished ApoEinduced stimulation of Ab42 secretion from human neurons co-cultured with MEFs without altering baseline Ab42 secretion ( Figure 5D ) and decreased Ab42 secretion from human neurons co-cultured with glia ( Figure S6C ).
The sg2-targeted sequence in the APP gene promoter conforms remarkably well to the consensus sequence of dimeric AP-1 transcription factors containing cFos, cJun, and/or other partners, suggesting that ApoE-stimulated MAP kinase signaling activates APP transcription by stimulating AP-1 ( Figure 5A ). To test this hypothesis, we examined cFos phosphorylation (Monje et al., 2003) . Strikingly, ApoE2, ApoE3, and ApoE4 stimulated cFos phosphorylation 2-to 6-fold in human neurons co-cultured with MEFs and acted with the same potency rank order of ApoE4 > ApoE3 > ApoE2 as DLK protein levels, MKK7 and ERK1/2 phosphorylation, APP transcription, and Ab synthesis ( Figure 5E ). Moreover, using an APP promoter reporter construct with wild-type or mutant AP-1 transcription factor binding sites (Wade et al., 1992) , we confirmed that ApoE2, ApoE3, and ApoE4 enhanced transcription from the APP promoter in an AP-1-dependent manner, again with the same ApoE4 > ApoE3 > ApoE2 potency rank order ( Figure 5F ). Furthermore, ApoE3 not only stimulated transcription of APP but also that of cFos ( Figure S6D ), which is a target of AP-1 in a positive feedback loop (Karin, 1995) . Again, stimulation of APP and cFos transcription by ApoE3 was specific, as it was not observed with MG132-induced stress and was not inhibited by JIP3 knockdown ( Figure S6D ). In addition, ApoE3 did not stimulate cJun transcription, which, however, was induced by MG132 in a JIP3-dependent manner.
Finally, to further probe the role of cFos in ApoE-stimulated APP transcription, we tested the effects of dominant-negative cFos (DN-cFos) overexpressed in human neurons (Olive et al., 1997) . DN-cFos did not alter baseline APP mRNA and protein levels but completely blocked increases in these levels induced by ApoE2, ApoE3, or ApoE4 (Figures 5G and 5H) . Thus, ApoE activates a DLK-dependent MAP kinase signaling pathway that induces cFos phosphorylation, which stimulates AP-1 and enhances APP synthesis via a direct effect on the APP gene promoter.
DLK-Activated AP-1-Dependent Signaling Regulates APP Transcription in Mouse Neurons in Culture and
In Vivo Do mechanisms similar to those we defined in relatively immature human neurons operate in more mature mouse neurons? To address this question, we examined dissociated cultures of neurons and glia from mouse cortex or hippocampus. ApoE had no effect on APP levels or Ab synthesis in these cultures, which is expected because ApoE and other factors are abundantly produced by their constituent glia ( Figures 6A, S7A , and S7B). However, DLK knockdowns decreased the steadystate levels of MKK7 and ERK1/2 phosphorylation, APP mRNA and APP protein levels, and Ab40 and Ab42 secretion in these neuron/glia cultures, suggesting that the same DLK / MKK7 / ERK1/2 / APP signaling pathway controls mouse App transcription in these neurons ( Figures 6B-6D, S7C , and S7D). Conversely, DLK and MKK7 overexpression in rescue experiments on the background of the DLK knockdown caused the opposite effect, with 2-to 4-fold increases in the steady-state levels of MKK7 and ERK1/2 phosphorylation, APP mRNA and protein levels, and Ab40 and Ab42 secretion ( Figures 6B-6D and S7D). Thus, glial factors likely stimulate neuronal APP and Ab synthesis by the same pathway in dissociated mouse neuron/glia cultures as in human neurons.
Next, we asked whether stimulation of App transcription in mouse neuron/glia cultures is also mediated by the AP-1-dependent activation of the mouse App promoter. Comparison of the human APP and mouse App promoter sequences revealed that the AP-1 binding sequence is conserved evolutionarily (Figure 6E) . Using a guide RNA for the AP-1 binding sequence in the mouse App promoter, we found that CRISPRi significantly suppressed APP mRNA and protein levels and decreased Ab40 and Ab42 secretion in mouse neuron/glia cultures (Figures 6F-6H and S7E-S7G). Thus, the same signaling pathway controls Ab production in human and mouse neurons.
Finally, we tested whether the pathway that controls APP production via cFos activation in cultured neurons operates in vivo. Owing to the multitude of secreted glial factors that stimulate the pathway, we decided not to address this question by manipulating mouse ApoE as one of multiple signaling factors. Instead, we tested in mice whether the downstream, final regulatory event, the activation of App transcription via AP-1 binding to its promoter, operates in vivo. For this purpose, we stereotactically injected into the cortex of newborn mice AAVs that express a control protein or DN-cFos, the dominant-negative form of cFos, or AAVs that express dCAS9 with a control guide RNA or (A) Human neurons synthesize $5-fold less APP when cultured on MEFs instead of glia; addition of ApoE2, ApoE3, or ApoE4 (each 10 mg/mL applied from D10 to 12) stimulates APP synthesis in human neurons on MEFs with an ApoE4 > ApoE3 > ApoE2 potency rank order, which is blocked by the ApoE receptor antagonist RAP (left, representative immunoblots; right, summary graphs; see also Figure S5 ). (B) ApoE2, ApoE3, and ApoE4 increase APP mRNA levels 3-to 4-fold with an ApoE4 > ApoE3 > ApoE2 potency rank order in human neurons cultured on Matrigel only. (C) ApoE2, ApoE3, and ApoE4 increase only APP, but not APLP1 or APLP2 mRNA levels in human neurons on MEFs with an ApoE4 > ApoE3 > ApoE2 potency rank order; ApoE-induced APP mRNA increase is inhibited by RAP and the MAP kinase inhibitor U0126, but not by the PI3K inhibitor Wortmannin. (D) Recombinant cholesterol-free ApoE2, ApoE3, and ApoE4 produced in bacteria stimulate APP mRNA levels in human neurons on MEFs similar to recombinant ApoE2, ApoE3, and ApoE4 produced in HEK293 cells. (E) Inhibition of DLK by shRNAs or MBIP blocks ApoE3-induced increases in APP protein levels, whereas DLK and MKK7 overexpression during rescue experiments constitutively increases APP protein levels independent of ApoE3. Note that DLK protein levels were not affected by MKK7 manipulations (left, representative blots; right, summary graphs). (F) Knockdown of the JNK scaffold JIP3 has no effect on ApoE3-induced activation of the DLK / MKK7 / ERK1/2 signal transduction cascade but blocks induction of the JNK MAP kinase cascade during the stress response to MG132. Human neurons on MEFs were infected with lentiviruses expressing a control shRNA or a JIP3 shRNA at D4; treated with control medium, ApoE3 (10 mg/mL), or MG132 (0.1 g/L) for 2 hr at D10; and analyzed by immunoblotting (left, representative blots; right, summary graphs). Data are means ± SEM (n R 3 independent experiments for all bar graphs); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) was evaluated with oneway ANOVA and Tukey's post hoc test in pairwise comparison (A-D and F) or comparisons to controls (E) . For further data and controls, see Figures S4 and S5 . See also Figure S3 . the guide RNA directed to the AP-1 binding sequence of the App promoter, thereby attempting to perform in vivo CRISPRi (Figures 7A and S7H) . We found that both manipulations significantly suppressed APP expression at the protein and mRNA levels (Figures 7B, 7C , S7I, and S7J). L1-CAM, Hsc70, and GDI as control proteins were not changed. Both manipulations only partially decreased APP levels, as would be expected for an impairment of only one element in the App promoter, and thus provided a specificity control. To the best of our knowledge, CRISPRi has not previously been attempted in vivo, and its applicability for promoter mapping in living mice enables attractive future studies that obviate the need for expensive transgenic experiments. Thus, the AP-1-dependent regulation of APP expression operates physiologically in vivo.
DISCUSSION
In order to examine the biological functions of ApoE in brain and to explore the contribution of different ApoE isoforms to AD pathogenesis, we here have studied human neurons that were cultured in complete isolation from glial cells and in the absence of serum. This approach enabled us to monitor neuronal responses to different ApoE isoforms in the absence of confounding glial signals, such as endogenous ApoE that is abundantly secreted by cultured glia. Our results reveal that ApoE activates a non-canonical MAP kinase signaling pathway by binding to cell-surface ApoE receptors. This pathway consists of DLK as MAP kinase kinase kinase that phosphorylates MKK7 as MAP kinase kinase, which in turn phosphorylates ERK1/2 as MAP kinases ( Figure 7D ). Activated ERK1/2 then phosphorylates cFos, a subunit of AP-1 transcription factors; cFos phosphorylation stimulates AP-1-dependent APP gene transcription via an AP-1-binding site in the APP gene promoter. The resulting increase in APP enhances Ab levels. Importantly, we show that the three genetic isoforms of human ApoE (ApoE2, ApoE3, and ApoE4) exhibit differential potency in stimulating the DLK / MKK7 / ERK1/2 MAP kinase pathway, cFos phosphorylation, APP gene transcription, and Ab synthesis. This differential potency may be relevant for AD because ApoE4 constitutes the most important genetic risk factor for AD, whereas ApoE2 protects against AD (Strittmatter et al., 1993; Holtzman et al., 2012; Kanekiyo et al., 2014; Wang and Eckel, 2014) . We posit that even though ApoE is only one of several signaling factors that drive APP and Ab synthesis in neurons, the higher signaling efficacy of ApoE4 than ApoE3 in stimulating APP and Ab synthesis may cause a cumulative effect over an individual's lifetime, thus accounting for the increased Ab concentrations and AD incidence in individuals expressing ApoE4.
In our experiments, the culture of human neurons maintained independent of glia or serum allowed unprecedented control over exogenous signals acting on these neurons. Moreover, application of CRISPRi to map transcription-factor-binding sequences in a promoter in cultured cells and in vivo might prove generally useful for mapping promoter elements. Conceptually, the finding that ApoE activates a non-canonical MAP kinase pathway involving ERK1/2 phosphorylation by MKK7, but not JNKs, and that ApoE acts here in a receptor-dependent, cholesterol-independent manner were surprising. The upstream mechanism involved-stabilizing DLK by preventing its rapid proteasomal degradation-was also unexpected, as was the downstream effector pathway whereby cFos phosphorylation stimulates APP transcription via a specific AP-1 binding sequence that is evolutionarily conserved and that functions in vivo. Remarkably, ApoE upregulated only APP, but not its close homologs APLP1 and APLP2. Thus, our studies describe an unanticipated signal transduction pathway that links ApoE signaling to Ab synthesis in human neurons.
Definition of the non-canonical MAP kinase signal pathway mediated by DLK, MKK7, and ERK1/2 connects ApoE-dependent signaling to DLK, which performs important additional functions in synapse formation and neuronal regeneration (Yan et al., 2009; Hammarlund et al., 2009; Shin et al., 2012) . However, different from other DLK activities that appear to involve MKK4 and JNKs (Tedeschi and Bradke, 2013), we observed that ApoE-induced stimulation of DLK activates MKK7 and ERK1/2, which then regulates gene transcription via activation of cFos, suggesting that DLK may be a key signaling platform whose precise functional readout depends Human neurons on MEFs were infected at D4 with lentiviruses co-expressing BFP-tagged dCas9, various single RNAs (sgRNAs), and mCherry. Neurons were treated at D10 with ApoE3 (10 mg/mL), and APP mRNA levels were measured at D12. (C) CRISPRi of AP-1 binding sequence in human APP promoter blocks ApoE3-induced increase in APP protein, but not in ERK1/2 phosphorylation. Experiments were performed as for (B) , except that neurons were analyzed by quantitative immunoblotting (left, representative blots; right, summary graph). (D) CRISPRi of AP-1 binding sequence in human APP promoter suppresses ApoE-induced, but not basal Ab42, secretion from human neurons on MEFs. Experiments were performed as described for (B) . (E) ApoE activates cFos phosphorylation in human neurons co-cultured with MEFs with an ApoE4 > ApoE3 > ApoE2 rank potency order; cFos phosphorylation is blocked by the ApoE-receptor antagonist RAP (top, representative immunoblots; bottom, summary graphs). (F) AP-1 binding site in human APP promoter mediates ApoE stimulation of APP gene transcription. Human neurons cultured on MEFs were infected at D4 with lentiviruses containing APP-promoter-driven firefly luciferase and constitutively expressed Renilla luciferase (internal control), treated with ApoE (10 mg/mL) at D10, and analyzed at D12 (top, schematic of promoter reporter construct; bottom, summary graph of luciferase expression normalized to the Renilla luciferase control). (G and H) Dominant-negative cFos (DN-cFos) suppresses ApoE induction of APP mRNA levels (G) and APP protein (H) . Data are means ± SEM (n R 3 independent experiments for all bar graphs); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001; n.s., not significant) was evaluated with one-way ANOVA with Tukey's post hoc test or Student's t test. In (B) and (C) , the difference between ÀApoE3 and +ApoE3 is significant for control, sg1 and 3-6 groups (p < 0.001 as indicated), but not for sg2 (n.s.). For additional data, see Figure S6 .
on the location of that signal and the state of the neurons. Our in vivo experiments in mice show that the downstream signaling mechanisms that we defined normally regulate APP expression, documenting the physiological significance of this pathway. Although the upstream ApoE signal is redundant with other glial signals, redundancy of a function does not mean it is unimportant. Moreover, chronic small changes in the efficacy of a function-such as ApoE2 versus ApoE3 versus All experiments were carried out in dissociated mixed mouse neuron/glia cultures, in which endogenous glia factors maximally stimulate ApoE-dependent signaling pathways. (A) Exogenous ApoE3 has no effect on APP mRNA levels in neuron/glia cultures from mouse cortex, but inhibition of DLK by MBIP overexpression decreases APP mRNA levels, whereas DLK or MKK7 overexpression increase APP mRNA levels. Neuron/glia cultures were transduced with lentiviruses at day in vitro 4 (DIV4), treated with ApoE3 (10 mg/mL) at DIV10, and analyzed by RT-PCR at DIV12. (B) DLK knockdown decreases APP and DLK protein levels in neuron/glia cultures from mouse hippocampus and additionally suppresses steady-state phosphorylation of ERK1/2 and MKK7, whereas rescue overexpression of either DLK or MKK7 increases APP protein levels and MKK7 and ERK1/2 phosphorylation. (C and D) DLK knockdown decreases APP mRNA levels (C) and Ab secretion (D) in neuron/glia cultures from mouse hippocampus, whereas rescue overexpression of either DLK or MKK7 increases APP mRNA levels (C) and Ab40 and Ab42 secretion (D) . (E) Alignment of the human APP and murine App promoter sequences containing the AP-1 binding site demonstrates a high degree of conservation. (F and G) CRISPRi-mediated inhibition of AP-1 binding to the App promoter in neuron/glia cultures from mouse hippocampus suppresses APP mRNA (F) and protein levels (G) . (H) CRISPRi-mediated inhibition of AP-1 binding to the App promoter decreases Ab40 and Ab42 secretion in neuron/glia cultures from mouse hippocampus. Data are means ± SEM (n R 3 independent experiments for all bar graphs); statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001) was evaluated with oneway ANOVA and comparing to control with Tukey's post hoc multiple comparisons (A-D) and Student's t test (F-H) . For additional data, see Figure S7 .
ApoE4 signaling-could cumulatively cause major effects over the decades of the life of a person.
Our observation that ApoE2, ApoE3, and ApoE4 differentially activate APP transcription and Ab synthesis reveals a striking [DNcFos] and EGFP plus dCAS9 with either a control guide RNA or a guide RNA directed to the App promoter AP-1 binding site) were stereotactically injected into the cortex of anesthetized newborn mice (left), and cortex expressing EGFP was analyzed at P7 to P8 (right). (B and C) Suppression of cFos signaling using DNcFos (A; n = 5 mice for test and control) or CRISPRi of the AP-1 binding sequence of the App promoter (B; n = 6 mice for test and control) selectively decreases APP expression in vivo (for mRNA measurements, see Figure S7 ). Data are means ± SEM (n.d., not detectable); statistical significance was evaluated with Student's t test (***p < 0.001). (D) Schematic of the ApoE signaling pathway that controls APP transcription and Ab production via activation of the DLK MAP kinase cascade. See text for details. ApoE is proposed to increase AD risk by causing an incremental chronic increase in APP abundance and Ab secretion, with ApoE4 being more and ApoE2 being less efficacious than ApoE3 in a parallel to their effects on AD risk.
parallel to the contribution of these genetic ApoE variants to AD risk, suggesting that the differential activation of Ab synthesis by ApoE2, ApoE3, and ApoE4 may contribute to their role in AD pathogenesis. However, we do not mean to imply that the differential efficacy of ApoE2, ApoE3, and ApoE4 in activating APP transcription and Ab synthesis is the only mechanism by which these genetic isoforms influence AD risk. In recent years, major progress was achieved in the understanding of APP cleavage by a-, b-, and g-secretases, and plausible hypotheses describe how these proteases may contribute to AD pathogenesis and how rare missense mutations in APP and g-secretase may cause familial AD (De Strooper and Karran, 2016; Goedert, 2015) . How APP transcription is regulated and what differentiates the APP gene from the closely related APLP1 and APLP2 genes that are not linked to AD is much less clear. Genetic variations in the APP promoter correlate with AD risk (Lahiri et al., 2005; Brouwers et al., 2006) , and APP gene duplications cause early-onset AD (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) , showing that APP expression is indeed important for AD pathogenesis. The finding that ApoE increases APP transcription 4-to 6-fold in human neurons by activation of cFos-containing AP-1 transcription factors suggests that it may be possible to influence APP transcription pharmacologically as an approach to AD prevention or even therapy.
Our results raise important new questions, both about the mechanism and the conceptual implications of the signaling pathway that we describe. For example, which ApoE receptor mediates activation of DLK and how is the ApoE signal transduced? ApoE receptors bind to adaptor proteins, such as Disabled-1 and X11/Mints, thereby mediating signal transduction (Gotthardt et al., 2000) . Clearly, a similar pathway could operate in DLK activation. Another mechanistic question regards the differential efficacy of ApoE2, ApoE3, and ApoE4 in activating ApoE receptors-is this effect due to different binding affinities or to different agonist potencies? This important issue can be addressed once the relevant ApoE receptor for signaling in neurons has been identified ( Figure 7D ). Among broader questions, those regarding the general function of the ApoE-stimulated MAP kinase signaling pathway may be paramount-what is its overall role and which other biological processes are regulated by this pathway? Moreover, what is the biological function of APP, an issue that has been debated for decades, and why is expression of APP, but not of APLP1 or APLP2, increased by ApoE signaling? These and other questions raised by the present studies provide fertile grounds for future advances in understanding not only brain signaling pathways but also their contribution to AD pathogenesis.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human neurons induced from embryonic stem cells and iPS cells H1 human ES cells were obtained from WiCell Research Resources (Wicell, WI), and iPS cell lines EB and SKC from the Stanford Stem Cell Core. Human neurons were generated from H1 and iPS cells essentially as described ) with modifications described in METHOD DETAILS.
Mice CD1 wild-type mice Crl:CD1(ICR) purchased from Charles River Laboratories were used in vitro for dissociated cultures of hippocampal neurons, glia and murine embryonic fibroblasts (MEFs), and in vivo for AAV injections (see METHOD DETAILS). Both male and female animals were used, and randomly allocated to experimental groups. All animal usage followed the guidelines of and was over- 
METHOD DETAILS
Culture of various principal types of cells Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. H1 human ES cells were obtained from WiCell Research
Resources (Wicell, WI), maintained in feeder-free condition using mTeSR1 medium (Stem Cell Technologies), and used at intermediate ($50) passage numbers to generate human induced neuronal (iN) cells . Cells were cultured as described . Mouse glia were cultured from the cortex of newborn CD1 mice. The cortex was dissected, digested with papain 10 U/ml for 20 min at 37 C, and harshly triturated. Cells were plated onto T75 flasks in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). After reaching 80%-90% confluence, glial cultures were trypsinized and re-plated at lower density (1:3-4) in DMEM + 10% FBS. This re-plating procedure was repeated 2-3 times (typically 3-4 days apart) to remove mouse neurons before cultured glia were used for analysis or co-culture experiments with human neurons. No antibiotics or other drugs were used in glial cultures.
Murine embryonic fibroblasts (MEFs) were isolated from mouse embryos of CF-1 strain (Harlan Laboratories, Inc.) harvested at 12.5-13.5 postcoitum (p.c.). Briefly, embryos were dissected out of terminally anesthetized mice. The head and internal organs were removed, and the remaining carcasses were finely minced, trypsinized into single-cell suspensions, and plated onto T75 flasks. The cultured MEFs (P0) were frozen or expanded for up to 3 times (P3) before they were used for experiments.
Mouse hippocampal cortical neurons were cultured from newborn CD1 mice according to standard procedures . In short, hippocampi or cortices were dissected, papain-digested, and triturated. The dissociated cortical neurons were plated on matrigel-coated glass coverslips, and maintained in Neurobasal-A (NBA) medium with B-27 supplement. No FBS was ever added into the mouse cortical cultures. The lentiviral infection if applicable was performed at DIV4, and ApoE treatment (10 mg/ml) was applied from DIV 7. Cultures were harvested on DIV12-14 for indicated biochemical assays.
Generation of neurons from human ES and iPSC cells
Human neurons (iN cells) were generated from H1 and iPS cells essentially as described with the following modifications ( Figure S1A ): ES cells were detached with accutase and plated onto matrigel-coated 6-well plates (4x10 4 cells/well) on day À2. Lentiviruses expressing Ngn2 and rtTA were prepared as described below, and added to the ES cells in fresh mTeSR1 medium (Stem Cell Technologies) on day À1. Doxycycline (2 mg/l, to activate Ngn2 expression) was added on day 0 (D0) in DMEM-F12 medium with N2 supplement without morphogens. Puromycin (1 mg/l) was added on D1 in fresh DMEM-F12/N2 + doxycycline medium for selection up to 24 hr. On D2, differentiating neurons were detached with accutase and re-plated on cultured mouse glia, MEFs, or just matrigel-coated 24-well plates (200,000 cells/well), and maintained in NBA/B-27 medium with no doxycycline. Various lentiviral infection of neurons were performed on D4 as described below; ApoE incubations were initiated on D10 and lasted until neurons were analyzed for different parameters. For mRNA and protein measurements, the assays were performed on D12 after ApoE treatments of 2 days, unless otherwise specified in time course studies. For immunoblotting analysis of protein phosphorylation, the ApoE was administered for 2 hr, and neuronal cultures were harvested immediately.
AAVs packaged with AAV-DJ capsids were used for high efficiency of in vivo neuronal infection. AAV vectors with pHelper and pRC-DJ were transfected into HEK293 cells, which were collected and lysed 72 hr later. The virus preparations were concentrated from cell lysates by fractioning with iodixanol gradient (40%) and filtering with 100,000 MWCO tube filter. The virus titer was measured by infecting HEK293 cells and adjusted to 1.0 3 10 7 infectious units/ml for brain injection. The AAV vectors used in DN-cFos experiment ( Figures 7B and S7H-S7J ) express P2A-EGFP (control) or DN cFos-P2A-EGFP under the control of Synapsin-1 promoter. The AAV vectors used in CRIPSRi experiments are described in the following section and also express EGFP as a marker for dissection of infected brain tissues for further assays.
The AAVs were injected into the prefrontal cortex of P0-P1 mouse pups. Neonatal mice were first cryo-anesthetized in an ice-cold chamber, and then secured in a prone position with a custom-made clay mold and adhesive bandage. A syringe pump injector equipped with pulled glass micropipette of beveled tip at $50 mm diameter was used for injections. The insertion location of micropipette was guided by vascular anatomy, rostral to inferior cerebral vein and close to superior sagittal sinus. Each pup received one injection in only one hemisphere, with a total of 0.5 mL of AAV suspension at 2 different depths. The overall survival was nearly 100%. The injected pups were sacrificed at P7-8, and the brains were harvested for dissection of infected tissues marked by green fluorescence under blue-light illumination from a hand-hold LED lamp (Nightsea, excitation 440-460 nm, see Figure S7H ) The dissected tissues were then lysed for immunoblotting and qPCR ( Figures 7A-7C and S7I-S7J).
Suppression of gene expression using RNAi, CRISPR/Cas9, or CRISPRi/dCas9 RNAi of DLK, LZK or JIP3. shRNAs to DLK (sequence: ACTCGTATTCCTTGTACATAG, TRC number: TRCN0000231658), to LZK (sequence: CCTGATGAGTTAGCTGATAAA, TRCN000019471) and to JIP3 (sequence: GTTCTCAGTGCGCGATGATTT, TRCN0000422388) and the control shRNA (sequence: TAAGGCTATGAAGAGATAC, SHC016) were purchased from Sigma-Aldrich in lentiviral vector pLKO.1-puro. The DLK shRNA targets the 3 0 UTR of DLK mRNA and does not affect expression of rescue DLK, while the control shRNA (non-target, Sigma-Aldrich SHC016) contains at least four mismatches to any human or mouse gene and was demonstrated by the manufacturer to target zero gene using microarray analyses.
MKK7 CRISPR. Lentiviral CRISPR/Cas9-mediated inhibition of human MKK7 expression was performed using a plasmid (lenti-CRISPR v2; Addgene plasmid # 52961) that co-expresses mammalian codon-optimized Cas9 nuclease with a single guide RNA (sgRNA). The MKK7 sgRNA (sequence: GCTTCAGCTTTGCTTCCAGG) targets exon 1 with a cleavage site at amino acid 13 and was designed using web-based tools (Doench et al., 2014) . The control sgRNA targets EGFP (EGFP sgRNA4; sequence: GGAGCG CACCATCTTCTTCA; Addgene plasmid # 51763) and was cloned into the same Cas9-expressing vector.
CRISPRi of the human APP promoter was performed essentially as described (Larson et al., 2013) . Six sgRNAs were designed to probe the human APP promoter region from 554 base pairs 5 0 to 147 base pairs 3 0 of the major transcription start site +1 at nucleotide 9001 in GenBank D87675.1 ( Figure 5A ). The sgRNA sequences are: sg1, ATTTCCTTTAAGCTTCACTCGTT; sg2, GCGGGGTCGGAT GATTCAAGCT (AP-1 site); sg3, GCCGGGGAGCGGAGGGGGCGCG; sg4, GCGCGAGCGGGCGCAGTTCCCCGG; sg5, CGCTCGGGCTCCGTCAGTTTCCT; sg6, GAGGAGCGTGCGCGGGGGCCC. One sgRNA was also designed to target the wellconserved AP-1 site on mouse APP promoter, (sgApp AP-1, GGGTCGGGTGACTCAAGCTCGCG). For in vitro experiments , the sgRNAs were cloned into a mCherry-co-expressed lentiviral plasmid (pgRNA-humanized; Addgene plasmid # 44248). A synthetic sgRNA targeting GFP was inserted into this pgRNA-humanized to construct the control plasmid (pU6-sgGFP-NT1; Addgene plasmid # 46914). The catalytically dead Cas9 (dCas), fused to blue fluorescent protein (BFP) and containing tandem nuclear localization sequences (2X NLS), was expressed via another lentiviral plasmid, pHR-SFFV-dCas9-BFP (Addgene plasmid # 46910). For in vivo experiments of AAV injection, the expression of sgApp AP-1 and a control sgRNA sequence targeting LacZ (sgLacZ, sequence: TGCGAATACGCCCACGCGAT) was driven by human U6 promoter on an AAV vector that expresses EGFP as a marker under the control of ubiquitin promoter. The dCas9, HA-tagged, was expressed via another AAV plasmid, AAV-CMV::NLS-dSaCas9(D10A,N580A)-NLS-3xHA (Addgene plasmid # 61594). The efficacy of the inhibition of gene expression by RNAi, CRISPR/Cas9 or CRISPRi/dCas9 was assessed by qRT-PCR and immunoblotting.
Immunofluorescence labeling experiments
Immunofluorescence staining experiments and image acquisition and analyses were performed essentially as described (Pak et al., 2015; Patzke et al., 2016) . Briefly, cultured neurons were fixed in 4% paraformaldehyde, 4% sucrose in PBS, permeabilized with 0.2% Triton X-100 in PBS, and blocked with 5% goat serum in PBS. Cells were incubated with primary antibodies diluted in blocking buffer overnight at 4 C, washed 3 times, and incubated with secondary antibodies in blocking buffer for 1 hr at room temperature. Samples were then mounted on glass slides for confocal imaging. The primary antibodies were listed in Key Resources Table. The Alexa 488, Alexa-546-, and Alexa-633-conjugated secondary antibodies were used (Invitrogen). For analysis of neuronal cell body size and total neurite length (Figure 1B and 1C) , neurons were sparsely labeled with GFP by liposome transfection (Lipofectamin 2000, Life Technologies) with a FUGW construct (Addgene plasmid # 14883) at D9 and fixed at D10 to obtain fluorescent images of individual neurons. To compare the expression pattern of DLK and MKK7 between neurons and glia, co-cultures of human neurons and mouse glia were fixed and immunostained at D12 ( Figure S2B ).
Immunofluorescence signals were visualized using a Nikon A1 confocal microscope with constant image settings. For image analyses, Z stacked images were converted to maximal projection images and analyzed using NIS-Elements Confocal software (Nikon). Neurons were randomly chosen in confocal images.
For experiments investigating neuronal cell density ( Figures 1C and S3B ), lentiviral transduction of synapsin-1 promoter-driven mCherry tagged with nuclear localization signal (FSW-mCherry-NLS) was used to label all neuronal nuclei in the cultures. Epi-fluorescent live imaging was taken by Leica microscope coupled with digital camera DFC400 (Leica) and analyzed using ImageJ software (National Institutes of Health).
Immunoblotting and protein quantifications
Neurons and cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, plus a cocktail protease inhibitors (Roche)), and lysates were analyzed by SDS-PAGE in the presence of DTT (0.1 M). Immunoblotting and quantitative analysis were performed by a dual-channel infrared imaging system with fluorescence-labeled secondary antibodies (800CW and 680LT), an Odyssey Infrared Imager CLX and software Image Studio 5.2.5 (LI-COR Biosciences). Signals were normalized for Tuj1 probed on the same blots as loading controls. Antibodies used were listed in Key Resources Table. Gene expression analyses To determine the mRNA levels of genes of interest in cultured cells, quantitative RT-PCR measurements were performed on total RNA (isolated with PrepEase RNA Spin Kit, Affymetrix) using TaqMan probes with VeriQuest Probe One-Step qRT-PCR Master Mix (Affymetrix) and an Applied Biosystems 7900HT apparatus. The pre-designed TaqMan primer/probe sets were purchased from Integrated DNA Technologies and tested to show no or minimal cross-species reactivity in pure human neuronal and mouse glial cultures ( Figures S1B and S2A ). MAP2 and GAPDH were used as endogenous reference genes.
The assay ID of all used TaqMan primer/probe sets was: human MAP2, Hs. 
Luciferase assays of APP promoter reporter plasmids
The regulation of the APP promoter was probed in cultured neurons using the Dual-Luciferase Reporter Assay System (Promega) that allows sequential measurements in a single sample of luminescent signals of firefly luciferase transcribed from the APP reporter and Renilla luciferase transcribed from a control promoter. We inserted the wild-type human APP promoter region (from À554 to +147; PCR-amplified from human genomic DNA extracted from HEK293T cells) into the KpnI and BglII sites of the promoter-less firefly luciferase vector pGL3-Basic (Promega), and obtained a matching mutant APP promoter construct with an AP-1 site substitution (changing the TGATTC sequence to TAATTA) by site-directed mutagenesis. The wild-type or mutant APP reporter plasmids (500 ng) were introduced at D9 together with a control plasmid (pRL-TK; Promega) encoding Renilla luciferase transcribed from a the herpes simplex virus thymidine kinase (HSV-TK) promoter (50 ng) into cultured human neurons in 24 well plates by liposome transfection (Lipofectamin 2000, Life Technologies). The co-transfection of the control plasmid which constitutively expresses Renilla luciferase with the test plasmid enables normalization of the transfection efficiency and recovery during the cellular extraction for each sample in the reporter assays. Each reporter experiment included extracts from sham-transfected cells as a reference control.
At D10 (24 hr after transfection), cultured neurons were treated for 48 hr with control solution or ApoE2, ApoE3, or ApoE4 (10 mg/ml). Cell lysates were collected at D12 in passive lysis buffer (Promega), and dual luciferase reporter assays were performed according to manufacturer instructions using a plate-reading luminometer with reagent auto-injectors Apollo LB915 (Berthold Technologies). Samples were compared by subtracting the background activity of the reference control, and then normalizing the firefly luciferase activity of each sample to its Renilla luciferase activity. APP gene sequence analyses Human promoter sequences for APP, APLP1, and APLP2 were aligned using CLUSTAL multiple alignment algorithms and the MUSCLE (3.8) program. Nucleotides shared by all three sequences are indicated by an asterisk. The AP-1 consensus binding sequence is boxed, and the transcription start site (+1) marked in bold and boxed. The sequences targeted by sgRNAs (sg1-6) for APP CRISPRi are underlined. APP promoter mutations associated with AD (Theuns et al., 2006) are marked with shading and boxed: À118C/A, À369C/G, and À534G/A. For the sequence alignment used, see Data S1.
Enzyme-linked immunosorbent assay of Ab All Ab measurements were performed using ELISA kits listed in Key Resources Table according to the manufacturer's instructions. Cultured neurons were washed 3 times on D10 with NBA/B27 to remove existing Ab, and treated with control solution or ApoE2, ApoE3, or ApoE4 (10 mg/ml in NBA/B27, 0.5 mL per well on a 24-well plate) for 48 hr. The culture medium was harvested at D12 to examine the concentration of secreted Ab variants. The cultured neurons were then washed for 3 times with PBS, and the wash buffer from the last wash was collected and analyzed for complete removal of ApoE and soluble Ab by immunoblotting of ApoE and Ab ELISA. After the washes, lysis buffer (TBS, 1% Triton X-100, 50 mL per well) was added, and the levels of cellular Ab extracted in cell lysates were measured by ELISA. The HEK293 ApoE proteins (medium supernatants from ApoE-expressing HEK293-F cultures; Methods, Recombinant ApoE and RAP proteins, A), media from mouse glial and cortical cultures were also subjected to ELISA and confirmed to be free of human Ab.
Non-radioactive in vitro kinase assay Recombinant human ERK2/MAPK1 were produced in E. coli bacteria (BL21 strain), described as above. The cDNA encoding human ERK2 (NM_002745.4) was synthesized as a gene fragment (gBlock, Integrated DNA Technologies), cloned into pGEX-KG vector, and expressed in bacteria as GST fusion proteins with a linker peptide sequence recognized by rhinovirus 3C protease. At the end of aforementioned purification process, GST cleavage by rhinovirus 3C protease was carried out in kinase buffer: 25 mM Tris-HCl (pH 7.5), 5 mM beta-glycerophosphate, 2mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2. The yield was around 2-5 mg from half a liter culture of E. coli BL21 harboring pGEX-ERK2.
Flag-tagged human MKK7 proteins were expressed in pure human neurons (iN cells) by lentiviral transduction (day 4 to day 10), and activated by ApoE stimulation (10 mg/ml for 2 hr on day 10) as described earlier. The gene fragment of human MKK7 (NM_001297555.1) was synthesized and cloned into AgeI and EcoRI sites on FUGW vector (Addgene plasmid # 14883). After mock or ApoE stimulation, human neurons were lysed with non-denaturing cell lysis buffer and brief sonication. Cell lysis buffer: 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin, and 1 mM PMSF added immediately before use. The immunoprecipitation of unactivated or ApoE-activated Flag-MKK7 was performed by incubating cell lysates of mock-or ApoE-stimulated human neurons with Flag-beads (Sigma A2220, mouse) or HA-beads (control, Sigma A2095, mouse) in cell lysis buffer, overnight at 4 C. For each condition, 50 mL of 50% flurry beads were first washed twice with cell lysis buffer and incubated with neuronal cell lysate collected from a whole 6-well plate of cultured human neurons ($4 million cells). After pull-down, the beads were washed twice with cell lysis buffer and once with kinase buffer, and then reconstituted as 50% flurry with kinase buffer. 10 mL of immunoprecipitated beads were eluted by adding 10 mL of 2X SDS-PAGE buffer. The ApoE-induced MKK7 phosphorylation and MKK7 pull-down efficiency were analyzed by immunoblotting with p-MKK7 (Cell Signaling 4171, rabbit) For in vitro kinase assays determining whether ApoE-activated MKK7 phosphorylates ERK2, 200 ng of recombinant human ERK2 was added into immunoprecipitated beads pelleted from 40 mL 50% flurry: Flag-beads pulling down unactivated or ApoE-activated Flag-MKK7, or control HA-beads. The reactions were done in 40 mL kinase buffer supplemented with 0.1 mM ATP at 30 C for 30 min, without or with U0126 50 mM. The reaction were terminated by pelleting down beads and adding 10 mL 5X SDS-PAGE buffer into the harvested supernatants ($40 ml). The phosphorylation of ERK2 was analyzed by running 20 mL of each reaction mixture supernatants for SDS-PAGE and immunoblotting using anti-ERK (Cell Signaling 4695) and anti-p-ERK (Cell Signaling 9106) antibodies. Cycloheximide chase assay to determine DLK protein stability The degradation rate of DLK protein was analyzed by quantitative immunoblotting after cycloheximide chase assay. Cycloheximide treatments were performed by adding cycloheximide (0.1 g/l; Sigma) without or together with ApoE3 (10 mg/ml) to cultured human neurons on MEFs at D10. At the indicated time points, neurons were lysed and immunoblotted for DLK protein levels. The data of DLK relative intensity at 0h, 2h, 4h and 6h, after normalization to loading control Tuj1, were fit to an exponential decay function (first-order kinetics, A = A 0 e kt ) to estimate the degradation rate constant (k, hour -1 ). The half-life time (t 1/2 ) is further calculated from the constant (t 1/2 = ln(2)/k) to determine the time required for 50% degradation of DLK protein without or with ApoE3.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantitative data are presented as means ± SEM. All experiments were independently repeated at least three times. Statistical analyses were conducted using Prism 6 software (GraphPad Software). Statistical comparisons between groups were analyzed for significance by one-way analysis of variance (ANOVA) with Tukey's post hoc test and Student's t test. Figure S1 . Related to Figure 1 General experimental strategy for producing human neurons (A); Measurements of apoe mrna levels in mouse glia, human neurons, and mefs showing that only glia abundantly express apoe (B) ; Production of recombinant apoe2, apoe3, and apoe4 in transfected hek293 cells and bacteria (C); Measurements of cellular Figure 1D ) are also active in elevating neuronal APP protein levels. Data show cellular APP levels determined by quantitative immunoblotting under the conditions described in Figure 1D (left, representative immunoblot; right, summary graph of APP protein levels normalized to the internal loading control Tuj1). Note that conditioned glia medium (CGM) robustly increases neuronal (human) APP protein level (yellow bar), and that this increase is replicated by addition of recombinant human ApoE3 (brown bar) and IGF2 and IGFBP2 (black bars). The production and application of CGM and selected glia factors are described in detail in the methods. (B) Same as A, except that the effect of conditioned glia medium (CGM) and of various factors on the APP mRNA was tested. (A) Demonstration that exogenous ApoE3 has no effect on the very high levels of human APP and DLK proteins expressed in human neurons co-cultured with mouse glia (presumably because glial factors already robustly activate DLK and APP levels [yellow bars]) and has no effect on glia or MEFs alone (in which human DLK and APP protein are not detectable (n.d.) under our conditions), but dramatically increases APP and DLK levels in human neurons co-cultured with MEFs (light blue/brown bars), or cultured on matrigel alone (blue bars). Cells cultured under the indicated conditions were treated with ApoE3 (10 mg/ml) from D10-12, harvested, and analyzed by immunoblotting. Left, representative immunoblots; right, summary graphs of protein levels normalized to Tuj1 in conditions containing human neurons, and plotted relative to the levels observed in neurons cultured on MEFs without ApoE3 (light blue bar). The glial marker GFAP was only detected in co-cultures of human neurons on mouse glia and in pure cultures of mouse glia.
Supplemental Figures
(B) APP synthesis in human neurons cultured on mouse glia are insensitive to ApoE owing to copious glial ApoE secretion, but are regulated by the same DLKdependent MAP kinase signaling pathway as the pathway that is activated by ApoE in the absence of glia. Human neurons co-cultured with glia were transduced with control lentiviruses or lentiviruses expressing DLK shRNAs without or with a DLK overexpression cassette, or expressing the DLK inhibitory protein MBIP at D4. Cells were treated with or without ApoE3 (10 mg/ml) from D10-12, and analyzed at D12 by quantitative immunoblotting for APP and DLK, using Tuji1 as a loading control and GFAP as a control for the glial co-culture (left, representative immunoblot; right, summary graphs of APP and DLK levels). Note that even in the presence of glia, APP levels can be upregulated by additional increases in DLK levels. (C) Similar to APP synthesis (see B), Ab40 and Ab42 levels in human neurons cultured on mouse glia are insensitive to ApoE owing to copious glial ApoE secretion, but are regulated by the same DLK-dependent MAP kinase signaling pathway as the pathway that is activated by ApoE in the absence of glia. Experiments were performed as described for B, except that the concentrations of human Ab40 and Ab42 were measured by ELISA in the medium as described in Figure S1 . Data are presented as means ± SEM; n R 3 independent experiments for all bar graphs; statistical significance (*p < 0.05, **p < 0.01; ***p < 0.001) was evaluated with one-way ANOVA and selected Tukey's post hoc comparisons, comparing test conditions to control. Non-significant comparisons are not identified. (A) ApoE isoforms do not affect Ab-synthesis in dissociated mixed cultures of mouse hippocampal neurons and glia, presumably because glia secretes copious amounts of factors. Cultures were treated with control solution or ApoE2, ApoE3, or ApoE4 (all 10 mg/ml) from DIV7 to DIV14, and Ab40 (left panel) and Ab42 (middle panel) levels in the culture medium were measured by ELISA at DIV14.
